NASDAQ · Stocky rates: Hold

MDA

$33.94 ▼ -0.96% as of 5 Aug, 20:00
66
/ 100
Hold

What Stocky thinks

Hold. MDA's 84/100 Growth Compounder Score reflects strong revenue momentum, but a 26.7× forward P/E demands flawless execution. Leadership Alignment (46.3/100) lags peer standards—no founder-CEO alignment or capped management ownership signals dilution risk. Growth premium is justified by market position, but limited margin of safety at current valuation.

Compounder Score
84/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
46/100
Founder-led, insider ownership, capital allocation history.
Value Score
50/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for MDA:

66
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 66/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

46
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

MDA (MDA) — frequently asked

Is MDA (MDA) a good investment right now?

Stocky rates MDA (MDA) at 66/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. MDA's 84/100 Growth Compounder Score reflects strong revenue momentum, but a 26.7× forward P/E demands flawless execution. Leadership Alignment (46.3/100) lags peer standards—no founder-CEO alignment or capped management ownership

What is MDA's Stocky Verdict?

MDA's current Stocky Verdict is 66/100, placing it in the "Hold" band. This composite combines a 84/100 Compounder score, 46/100 Leadership, Moat rating, and analyst signal.

Does MDA have a competitive moat?

Stocky hasn't finalised a Moat Score for MDA yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is MDA's leadership aligned with shareholders?

MDA scores 46/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to MDA?

Vulnerability Profile for MDA covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.

This is just the surface. See the whole picture on MDA.

Sign up free and unlock the full analysis on MDA — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering MDA — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for MDA.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how MDA changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to MDA?" · "Is MDA overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
66
/ 100 · Hold

Or jump straight to the interactive dashboard for MDA in the app.